# Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients

> **NCT00265226** · PHASE3 · COMPLETED · sponsor: **Ministry of Science and Technology, India** · enrollment: 1020 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **BIOLOGICAL:** Intra-dermal administration of Mycobacterium w

## Key facts

- **NCT ID:** NCT00265226
- **Lead sponsor:** Ministry of Science and Technology, India
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-12
- **Final completion:** 2011-03
- **Target enrollment:** 1020 (ACTUAL)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00265226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00265226, "Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00265226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*